吲哚胺2,3-双加氧酶免疫状态作为晚期远处转移性分化型甲状腺癌放射性碘疗效的潜在生物标志物

Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer

ES评分 0

DOI 10.3389/fonc.2022.871792
刊名
年,卷(期) 2022, 12(/)
作者
作者单位 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University;
Department of Neurology, Nanjing First Hospital, Nanjing Medical University;
Department of Oncology, Nanjing First Hospital, Nanjing Medical University;
Department of Nuclear Medicine, Affiliated Hospital of Jiangsu University;
Department of Emergency, Affiliated Hospital of Jiangsu University

摘要
目的: 宿主免疫会影响癌症治疗的效果,但免疫状态在放射性碘(RAI)治疗的分化型甲状腺癌(DTC)中的作用仍不清楚。在此,我们研究了吲哚胺2,3-双加氧酶(IDO)活性作为远处转移性DTC(dmDTC)患者对RAI治疗反应的生物标志物。 方法: 评估了接受RAI治疗的dmDTC患者在基线和RAI治疗后3个月时的血清IDO活性(犬尿氨酸及犬尿氨酸:色氨酸比值)。通过受试者工作特征(ROC)分析确定了这些生物标志物预测治疗反应的最佳截断值。研究了疾病结局、总生存期(OS)和无进展生存期(PFS)与IDO活性水平之间的关系。 结果: 较高的基线犬尿氨酸:色氨酸比值(>2.46)与较差的RAI反应以及较短的中位PFS(45个月 vs 未达到,p=0.002)和OS(78个月 vs 未达到,p=0.035)相关。高基线犬尿氨酸:色氨酸比值也与肿瘤浸润淋巴细胞数量的减少相关。较高的治疗后/治疗前犬尿氨酸比值(>1.69)与生存终点相关:较短的中位PFS(48个月 vs 未达到,p=0.002)和OS(68个月 vs 未达到,p=0.010)。良好的基线水平和良好的变化对应于更好的PFS和OS。 结论: 我们的结果提示,RAI也会改变dmDTC患者的IDO活性。IDO活性可以预测晚期dmDTC患者的进展和生存结局。血清IDO生物标志物水平可用于筛选可能从RAI治疗中获益的dmDTC患者,尽管还需要进一步的研究。
Abstract
Purpose: Host immunity influences the impact of cancer therapy but the effect of immune status in radioiodine (RAI)-treated differentiated thyroid cancer (DTC) remains obscure. Here we investigated indoleamine 2,3-dioxygenase (IDO) activity as a biomarker of response to RAI in patients with distant metastatic DTC (dmDTC). Methods: Patients with dmDTC receiving RAI were evaluated for serum IDO activity (kynurenine and kynurenine:tryptophan ratio) at baseline and 3 months after RAI. The optimal cut-off value for these biomarkers to predict response was established by receiver operating characteristic analysis. The relationship between disease outcomes, overall survival (OS) and progression-free survival (PFS), and IDO activity levels was studied. Results: Higher baseline kynurenine:tryptophan ratio (>2.46) was correlated with poorer RAI response as well as shorter median PFS (45 mo versus not reached, p=0.002) and OS (78 mo versus not reached, p=0.035). High baseline kynurenine:tryptophan ratio was also correlated with a reduced number of tumor-infiltrating lymphocytes. Higher post/prekynurenine ratio (>1.69) was associated with survival endpoints: shorter median PFS (48 mo versus not reached, p=0.002) and OS (68 mo versus not reached, p=0.010). Favorable baseline and favorable change corresponded with better PFS and OS. Conclusions: Our results suggest that RAI also alters IDO activity in dmDTC patients. IDO activity could predict progression and survival outcomes for advanced dmDTC patients. Serum IDO biomarker levels could be used to select dmDTC likely to benefit from RAI therapy, although further studies are necessary.
关键词
分化型甲状腺癌,放射性碘,吲哚胺2,3-双加氧酶(IDO),免疫抑制,预测因素
KeyWord
differentiated thyroid cancer, radioiodine, indoleamine 2, 3-dioxygenase (IDO), immune suppression, predictive factors
基金项目
页码 871792-/
  • 参考文献
  • 相关文献
  • 引用本文

LiangShi,RuiDuan,QiongJia,WenyuWu,JianmingZhou,ShaohuaLi,HaoZhang,XueXue. 吲哚胺2,3-双加氧酶免疫状态作为晚期远处转移性分化型甲状腺癌放射性碘疗效的潜在生物标志物 [J]. Frontiers in Oncology. 2022; 12; (/). 871792 - /.

  • 文献评论

相关学者

相关机构